

# Journal of Visualized Experiments

## Application of CRISPR Interference (CRISPRi) for Gene Silencing in Pathogenic Species of Leptospira

--Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - Author Produced Video
<b>Manuscript Number:</b>	JoVE62631R3
<b>Full Title:</b>	Application of CRISPR Interference (CRISPRi) for Gene Silencing in Pathogenic Species of Leptospira
<b>Corresponding Author:</b>	Luis Fernandes, Ph.D US Department of Agriculture Ames, Iowa UNITED STATES
<b>Corresponding Author's Institution:</b>	US Department of Agriculture
<b>Corresponding Author E-Mail:</b>	luis.fernandes@butantan.gov.br
<b>Order of Authors:</b>	Luis Fernandes, Ph.D Richard Hornsby Ana Nascimento Jarlath Nally
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$3000)
Please specify the section of the submitted manuscript.	Biology
Please confirm that you have read and agree to the terms and conditions of the author license agreement that applies below:	I agree to the <a href="#">Author License Agreement</a>
Please provide any comments to the journal here.	
Please indicate whether this article will be Standard Access or Open Access.	Open Access (\$3900)
Please confirm that you have read and agree to the terms and conditions of the video release that applies below:	I agree to the <a href="#">Video Release</a>

**TITLE:**

Application of CRISPR Interference (CRISPRi) for Gene Silencing in Pathogenic Species of *Leptospira*

**AUTHORS AND AFFILIATION:**

Fernandes, L.G.V.<sup>1,2,\*</sup>, Hornsby, R.L.<sup>1</sup>, Nascimento, ALTO<sup>2,#</sup>, Nally, J. E.<sup>1,#</sup>

<sup>1</sup>Infectious Bacterial Diseases Research Unit, National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, IA, U.S.A. <sup>2</sup>Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo 05503-900, Brazil.

# Jointly supervised this work

**Corresponding Author:**

Fernandes, L.G.V. ([luis.fernandes@usda.gov](mailto:luis.fernandes@usda.gov); [luis.fernandes@esib.butantan.gov.br](mailto:luis.fernandes@esib.butantan.gov.br))

**Co-authors:**

Richard L. Hornsby (richard.hornsby@usda.gov)

Ana Lucia Tabet Oller Nascimento (ana.nascimento@butantan.gov.br)

Jarlath E. Nally (jarlath.nally@usda.gov)

**KEYWORDS:**

*Leptospira*, leptospirosis, mutagenesis, CRISPR interference, gene silencing, conjugation

**SUMMARY:**

Here, the application of CRISPR interference (CRISPRi) for specific gene silencing in *Leptospira* species is described. *Leptospira* cells are transformed by conjugation with plasmids expressing dCas9 (catalytically “dead” Cas9) and a single-guide RNA (sgRNA), responsible for base pairing to the desired genomic target. Methods to validate gene silencing are presented.

**ABSTRACT:**

Leptospirosis is a global neglected zoonosis, responsible for at least 1 million cases per year and almost 60 thousand deaths. The disease is caused by pathogenic and virulent bacteria of the genus *Leptospira*, either by direct contact with the bacteria or indirectly by exposure to contaminated water or soil. Domestic and wild animals act as reservoir hosts of infection, shedding leptospires from colonized renal tubules of the kidney, via urine, into the environment. The generation of mutant strains of *Leptospira* is critical to evaluate and understand pathogenic mechanisms of infection. CRISPR interference (CRISPRi) has proven to be a straightforward, affordable, and specific tool for gene silencing in pathogenic *Leptospira*. Therefore, the methodological details of obtaining the plasmid constructs containing both dCas9 and guide RNA, delivery of plasmids to *Leptospira* by conjugation with the *E. coli* strain  $\beta$ 2163, and transconjugant recovery and evaluation, will be described. In addition, the recently described Hornsby-Alt-Nally (HAN) media allows for the relatively rapid isolation and selection of mutant colonies on agar plates.

**INTRODUCTION:**

Leptospirosis is a neglected worldwide zoonosis caused by pathogenic and virulent species of the genus *Leptospira*. In humans, the disease accounts for more than one million cases and 60,000 deaths per year worldwide<sup>1,2</sup>. So far, there is no long-term and effective vaccine for the disease. The identification of virulence factors and pathogenic mechanisms is pivotal to the development of better therapeutic and prophylactic strategies. Therefore, the ability to generate genetic mutations and assess the resulting phenotype is critical to functional genomic analysis<sup>3</sup>.

The construction of mutants in pathogenic *Leptospira* was considered, until now, inherently inefficient, laborious, costly, and difficult to implement. This scenario drastically changed with the application of the recent CRISPR interference (CRISPRi) to saprophytic<sup>4</sup> and pathogenic<sup>5</sup> leptospires.

Gene silencing is achieved by the expression of two components: a variant of the CRISPR/Cas (clustered regularly interspaced short palindromic repeat/CRISPR associated) enzyme Cas9 from *Streptococcus pyogenes*, called catalytically dead Cas9 (dCas9) and a single-guide RNA (sgRNA), that can be edited according to the desired target<sup>6-8</sup>. dCas9 protein, when bound to the sgRNA, is directed to specific DNA targets by Watson and Crick base pairing, causing a steric blockage to RNA polymerase elongation, resulting in gene silencing due to the obstructed gene transcription<sup>7</sup> (**Figure 1**).

This manuscript aims to describe the construction of the plasmid for expressing both dCas9 and sgRNA, conjugation between donor *E. coli*  $\beta$ 2163 and recipient *Leptospira* cells, transconjugant recovery, and finally, validation of selected mutant colonies.

## PROTOCOL

### 1. Protospacer definition and plasmid construction

NOTE: In this section, the first step is selecting appropriate protospacers for constructing the sgRNA and further ligation into pMaOri.dCas9, is described (**Figure 1**). This protospacer sequence comprises of a 20 nucleotides sequence against the desired target.

1.1 Obtain the nucleotide sequence of the gene of interest for silencing at GenBank (<https://www.ncbi.nlm.nih.gov/genbank>). Submit it to the CHOPCHOP webserver (<http://chopchop.cbu.uib.no/>), with parameters defined for *Streptococcus pyogenes* Cas9 and protospacer adjacent motif NGG after selecting the “**Fasta Target**”. Define the parameters to “CRISPR/Cas9” and PAM (protospacer adjacent motif) NGG.

1.2 Based on the results obtained, select protospacers with the best score possible (green arrow), that are located as close as possible to the 5' end of the coding region and, most importantly, are contained in the template (minus) strand since the sgRNA must pair to the coding strand of the gene for complete gene silencing.

NOTE: The NGG motif is not included in the final sgRNA sequence.

1.3 Use the *lipL32* promoter to express the single guide RNA that contains a variable 20 nucleotide sequence at the 5' end and a conserved dCas9 scaffold sequence. Merge the 20-nt sequence, termed protospacer, to the *lipL32* promoter (at its 5' end) and sgRNA scaffold (3'end) (**Figure 1B**).

NOTE: For a well-defined *lipL32* promoter, utilize the promoter region comprising -334 to the TSS (Transcription Start Site, based on Zhukova et al.<sup>9</sup>). Check the **Supplementary File** for the final sgRNA cassette.

1.4 Generate the sgRNA cassette by sequential PCR<sup>5</sup> or have it synthesized by a commercial provider.

1.5 After obtaining the cassette ligate it into pMaOri.dCas9 plasmid at the *XmaI* restriction site at both ends (cccggg)<sup>4</sup>.

1.5.1 Digest both the sgRNA cassette and pMaOri.dCas9 plasmid with *XmaI* restriction enzyme and proceed to ligation (**Figure 1B**).

1.5.2 Perform the cloning steps in the dT auxotrophic *E. coli* strain  $\pi 1^{10}$ , due to the pMaOri<sup>11</sup> (and by extension, pMaOri.dCas9) origin of replication, R6K-gamma.

NOTE: For a detailed protocol for ligation and clone selection, refer to previous publications by Fernandes and Nascimento<sup>12</sup>. sgRNA-guided dCas9 will bind to the coding strand of the selected gene of interest and, therefore, will obstruct RNA polymerase elongation (**Figure 1C**), resulting in gene silencing.

## 2. *Leptospira* transformation by conjugation

NOTE: A graphical scheme of this step is presented in **Figure 2**. To make HAN media and HAN plates, refer to Hornsby et al.<sup>13</sup> and Fernandes et al.<sup>5</sup>.

2.1 Grow pathogenic *Leptospira* cells at 29 or 37 °C in HAN media<sup>13</sup> under agitation by diluting a saturated culture in fresh HAN at 1:100; typically, *L. interrogans* serovar Copenhageni strain Fiocruz L1-130 takes 4-6 days to reach the appropriate cell density.

2.1.1. Ensure cultures reach an O.D. of 0.2-0.4 at 420 nm (2 to 5 x 10<sup>8</sup> cells/mL) before using for conjugation.

NOTE: Since HAN media changes color as cell densities increase (due to phenol red contained in DMEM media), centrifuge (4,000 x g, 15 min, room temperature) 1 mL of the culture media to remove leptospires and apply supernatant as a blank for measuring the O.D.

2.2. Transform the conjugative *E. coli* strain  $\beta 2163$ , auxotrophic for Diaminopimelic acid (DAP), with the plasmid pMaOri.dCas9 containing the sgRNA cassette. For *E. coli* transformation, use either heat-shock protocols or electroporation. Include transformation with the plasmid pMaOri.dCas9 with no sgRNA cassette as a control.

2.2.1. For heat-shock transformation, mix the plasmid DNA (100 ng) with chemically competent *E. coli* cells and incubate on ice for 30 min. Perform heat shock at 42 °C for 90 s and place it again on ice for 5 min. Recover the cells by adding 1 mL of LB media, incubate at 37 °C for 1 h and proceed to the plating.

2.2.2. For electroporation, use electrocompetent cells mixed with 100 ng of plasmid DNA. Use the following parameters for pulse: 1.8 kV, 100 Ω, and 25 μF. Recover the cells as explained above.

2.2.3. Plate the transformed donor *E. coli* cells in LB agar medium supplemented with Diaminopimelic acid (DAP) (0.3 mM) and spectinomycin (40 μg/mL) to select for plasmids.

2.3 For conjugation, select one colony from each plate one day before the day of conjugation (which is determined by monitoring the O.D. of cultures of leptospires).

2.3.1. Select one colony of *E. coli* β2163 from the empty pMaOri.dCas9, and one from pMaOri.dCas9sgRNA plates. Allow them to grow overnight in 10 mL of LB plus DAP and spectinomycin at 37 °C.

2.3.2. The next day, dilute the saturated cultures 1:100 in 10 mL of fresh LB plus DAP (do not include the antibiotic here) until OD<sub>420nm</sub> of 0.2-0.4. Normally, it takes 2-3 h for *E. coli* to reach these densities.

2.4. Inside a BSL2 biosafety hood, assemble a filtration apparatus by placing a 25 mm diameter, 0.1 μm pore size, mixed cellulose esters membrane filter on the top of the glass base. Place a 15 mL glass funnel on the top and hold both pieces with spring clamps. Connect the glass to a vacuum pump and add the cultures to the funnel for filtration.

2.5 Add 5 mL of *Leptospira* culture to the funnel. Add a volume of *E. coli* to constitute the 1:1 proportion based on the OD<sub>420nm</sub> values of both cultures. Turn on the vacuum pump and concentrate cells by filtration. After cell concentration in the membrane filter, carefully retrieve it. Ensure medium is filtered through the membrane.

NOTE: Filtration takes 5 to 10 min.

2.6 Place the filter on a commercially available EMJH plate (see **Table of Materials**) supplemented with DAP (0.3 mM). Ensure that bacteria side is up. Incubate the plates at 29 °C for 24 h.

NOTE: If HAN or supplemented in-house EMJH<sup>14</sup> plates are used, *E. coli* can proliferate and overcome the intended 1:1 proportion, which in turn can decrease conjugation efficiency<sup>5</sup>.

2.7 After 24 h, recover the filters from the plates and place each individual filter in a 50 mL conical tube.

2.8. Use 1 mL of liquid HAN medium to release the cells from the filter surface by extensive pipetting and vortexing.

2.9 Visualize the recovered mixed bacterial solutions by dark field microscopy to check for cell viability and motility, and *Leptospira*:*E. coli* proportions.

NOTE: At this stage, equivalent numbers of *E. coli* and *Leptospira* can be seen.

2.10 Spread 100-200  $\mu$ L of this culture onto HAN plates containing 0.4% inactivated rabbit serum and 40  $\mu$ g/mL spectinomycin. Incubate plates at 37 °C in a 3% CO<sub>2</sub> atmosphere.

NOTE: Normally, *L. interrogans* serovar Copenhageni strain Fiocruz L1-130 cells form colonies in 5-7 days on control plates and in 8-10 days on spectinomycin plates. At this stage, *E. coli* will not grow since they are auxotrophic for DAP.

2.11. As a control, dilute cultures at 10<sup>4</sup> leptospires/mL and add 100  $\mu$ L onto plates without antibiotic, for monitoring leptospiral growth.

### 3. Colony selection and transconjugant growth and validation

NOTE: Colonies should be apparent by day 10. However, they are not too easy to visualize. Normally at this time point, HAN plates are a bit opaque because of the dried cells that were spread and *Leptospira* colonies can appear as a transparent halo against the whitish background. It is recommended to view the plates at different angles to achieve different light incidence, therefore, making the colonies more apparent. At longer incubation times, colonies can acquire a denser appearance, and in this case, they present as milky halos against a dark background.

3.1 Add 100  $\mu$ L of liquid HAN media to each 1.5 mL microtube to recover mutants. Take at least 3 colonies from each plate.

3.1.1 With the aid of a micropipette tip, “dig” the agar to retrieve the colonies from the plates since leptospiral colonies can be subsurface.

NOTE: Agar is expected to be taken along at this stage. Colonies should be taken from control plates containing empty pMaOri.dCas9 plasmid, and plates with leptospires containing plasmids expressing both dCas9 and single guide RNA, designed for the target gene.

3.1.2 Dispense the collected colony in 100  $\mu$ L of HAN media in a 1.5 mL microtube and vigorously homogenize. At this stage, ensure maximal break of the agar integrity to release cells. Vortex the suspension for 10 s.

3.2 Visualize the recovered cells by dark field microscopy at a 200-400x magnification by adding a 5  $\mu$ L drop onto a glass slide and cover the samples immediately with a coverslip.

3.2.1 Confirm the presence of live and viable leptospires recovered from the colonies.

3.2.2 After visualization and confirmation of viable leptospires, transfer 100  $\mu$ L of cells to liquid HAN media containing 40  $\mu$ g/mL spectinomycin.

3.3 After growth in liquid HAN media, evaluate the cultures for the presence of the plasmid with primer pMaOri2 F (ACGCAATGTATCGATACCGAC) and R (ATAGGTGAAGTAGGCCACCC), which recognize the region that flanks the sgRNA cassette.

3.3.1. Collect 200  $\mu$ L of culture, centrifuge (4,000  $\times$  *g*, 15 min), discard the supernatant, and resuspend the resulting pellet in 20  $\mu$ L of water.

3.3.2. Use this suspension as a template for additional PCR, without the need for DNA extraction<sup>12</sup>.

**NOTE:** Cells with pMaOri.dCas9 will render an amplicon of 281 bp, compared to those containing the plasmids with the sgRNA cassette which will render an amplicon of 723 bp.

3.4 For confirmation of gene silencing, perform an immunoblot utilizing cell extracts from transconjugants containing only pMaOri.dCas9 (negative control) and pMaOri.dCas9sgRNA.

3.4.1. Apply the equivalent of  $5 \times 10^7$  cells per lane of the sodium dodecyl sulfate (SDS) polyacrylamide gel.

3.4.2. Electrotransfer proteins to a membrane for incubation with appropriate antibodies. Besides the antibody against the target gene for silencing, use another one for loading control.

3.5 Keep the mutant cultures in HAN media plus spectinomycin for maintaining the plasmid. If no antibiotics are applied to the media, complete gene silencing can be observed for at least three passages<sup>5</sup>.

## REPRESENTATIVE RESULTS

Even though the CG content in *Leptospira* spp. genomes is typically around 35%; virtually every gene is likely to contain the PAM 5'NGG 3'; this motif needs to be considered in the template strand. After inputting the coding sequence of a gene (from start to stop codons), based on the CHOPCHOP results, protospacers must be selected at the minus (-, template) strand. It is important to not include the NGG motif in the 20-nt sgRNA protospacer.

If conjugation is performed with a 1:1 donor:recipient cell proportion, for 24 h on the surface of EMJH agar plates plus DAP, and 200  $\mu$ L of the recovered bacterial suspension are spread onto HAN plus spectinomycin agar plates, transconjugants colonies should be visible at approximately 8-10 days. Spreading of this volume normally results in 20-40 colonies per plate (**Figure 3A**). In order to check for cell viability after conjugation, cells can be spread onto HAN plates with no antibiotic selection. In this case, colonies can be observed as soon as 7 days. HAN plates turn pale yellow in a 3% CO<sub>2</sub> atmosphere.

After colony picking and growth in liquid media plus spectinomycin, PCR using whole cells and pMaOri2 primers can be used for an initial quality check of the transconjugants (**Figure 3B**). *Leptospiral* cells containing the control pMaOri.dCas9 plasmid should result in an amplicon of 281 bp, while those cells containing the plasmid for silencing, that is, containing both dCas9

and sgRNA, should result in a 723 bp amplicon. pMaOri2 F and R primers were designed to flank the *Xma*I restriction site, which is the site used during sgRNA cassette ligation.

With the confirmation of plasmid presence, cells can be harvested from the media, washed twice with PBS, and then used to prepare a whole-cell extract for immunoblotting. If the silencing occurred, the target proteins, in this case, either LipL32 or both LigA and LigB, should be observed only in the wild type cells and in those containing pMaOri.dCas9; even with higher exposure times, no corresponding proteins should be visible in the cells containing pMaOri.dCas9sgRNA (**Figure 3C**).

If experiments to assess leptospiral virulence after gene silencing are planned, cultures used for conjugation should be low passage virulent *Leptospira*. After gene silencing is confirmed, several aliquots can be frozen as a backup. If the silenced gene has a measurable phenotype, e.g., based on previous work with recombinant proteins, cultures can be used for validation and, in this case, cells containing pMaOri.dCas9 only, can be included as a negative control.

## FIGURE LEGENDS

**Figure 1: Development of dCas9 and sgRNA expressing plasmid.** (A) A 20-nt long protospacer, followed by the *S. pyogenes* dCas9 PAM 5'-NGG-3', is selected within the template strand of the target gene so the subsequent sgRNA can perform Watson and Crick base pairing to the corresponding coding strand, resulting in complete gene silencing. (B) The sgRNA cassette is composed of the *lipL32* promoter, 20-nt protospacer, and dCas9 scaffold. The pMaOri.dCas9 plasmid is used as a backbone for sgRNA cassette ligation at the *Xma*I restriction site. The resulting plasmid, termed pMaOri.dCas9sgRNA is delivered to leptospires, and the expression of both dCas9 and sgRNA is responsible for the gene silencing. (C) sgRNA-directed dCas9 acts as a physical barrier to RNA polymerase elongation, therefore, hampering transcription.

**Figure 2: Schematic representation of conjugation protocol.** The desired *Leptospira* species is grown in HAN media, under agitation, until O.D. of 0.2-0.4 (mid-log phase) at 420 nm. One day before conjugation, a colony of recombinant donor *E. coli*  $\beta$ 2163 containing the plasmid of interest is picked from LB+DAP+Spc agar plates, as cells are grown overnight in liquid LB with the same supplementation. The next day, saturated *E. coli* cultures are diluted in LB plus DAP and grown until O.D. of 0.2-0.4 at 420 nm. Both donor *E. coli* and recipient *Leptospira* are mixed at 1:1 cell proportion onto the surface of a 0.1  $\mu$ m filter by a filtration apparatus under negative pressure. Then, filters are placed on top of the EMJH agar plates supplemented with DAP, and incubation proceeds for 24 h at 29 °C. The use of EMJH limits *E. coli* proliferation, and the intended 1:1 proportion is maintained. Bacteria are recovered from filters by pipetting with 1 mL HAN media, and suspensions are visualized under darkfield microscopy. Finally, 100-200  $\mu$ L of each suspension are seeded onto HAN agar plates containing 0.4% rabbit serum and incubated at 37 °C in 3% CO<sub>2</sub>. At this stage, DAP is omitted, and as a result, auxotrophic *E. coli* will not grow.

**Figure 3: Representative results for mutants' evaluation.** (A) Colonies from plates containing *Leptospira* transformed with empty pMaOri.dCas9 (negative control for further experiments) and plasmids pMaOri.dCas9sgRNA (with targeted gene silenced) are picked, vigorously



homogenized in liquid HAN and grown in liquid HAN containing spectinomycin. Recombinant cells can be validated by PCR with primers flanking the *Xma*I site within pMaOri.dCas9. (B) In this case, cells containing pMaOri.dCas9 only resulted in an amplicon of 281 bp, while those cells containing the plasmid for silencing, containing both dCas9 and sgRNA, showed a 723 bp amplicon. After confirmation of the presence of the plasmids, gene silencing was validated by immunoblot analysis. (C) Incubation with antibodies to both target protein and a loading control protein is recommended; in the representative immunoblot, whole-cell extracts from transconjugants containing pMaOri.dCas9 alone or with sgRNA cassettes targeting *lip*L32 (pMaOri.dCas9sgRNAlipL32) and both LigA and LigB (pMaOri.dCas9sgRNAligAB) genes are displayed. Co-incubation with anti-LipL32, anti-LigAB and anti-LipL41 (non-target, loading control) confirms that the expression of LipL32 protein is abolished in cells containing pMaOri.dCas9sgRNAlipL32 and both LigA and LigB in cells containing pMaOri.dCas9sgRNAligAB.

**Supplementary File: Single guide RNA (sgRNA) cassette sequence.** The sgRNA transcription is directed by the constitutive *lip*L32 promoter (bold nucleotides). sgRNA is composed of 20 nucleotides referring to the protospacer, responsible for base pairing to the coding strand of the target gene, and dCas9 scaffold sequence (underlined nucleotides). *Xma*I restriction sites (cccggg) are included at both ends for ligation at pMaOri.dCas9 plasmid.

## DISCUSSION

After the early sequencing of pathogenic<sup>15-18</sup> and saprophytic<sup>19</sup> *Leptospira* species, data mining of the genome shed light on several aspects of leptospiral pathogenesis. In most cases, protein function was explored by using the recombinant counterpart of putative leptospiral surface-exposed proteins and subsequent speculation of the native protein function<sup>20-26</sup>.

The generation of mutants, and evaluation of their respective phenotype, are key components of functional genomic analysis. Initial attempts to generate mutants in *Leptospira* spp. were achieved by random transposon mutagenesis<sup>27-30</sup>; however, after extensive and laborious analysis for inferring the identity of disrupted genes, it was noted that only 15% of all genes in *L. interrogans* serovar Manilae were disrupted<sup>27</sup>. Targeted gene knockout was further achieved by homologous recombination utilizing suicide plasmids to deliver an antibiotic resistance cassette flanked by homologous arms within the desired target<sup>31,32</sup>.

By applying these technologies, several aspects of leptospiral basic biology and virulence were explored<sup>31,33-37</sup>. The development of the *E. coli-Leptospira* conjugative shuttle vector, pMaOri<sup>11</sup>, allowed the delivery of components for episomal gene silencing.

It was previously shown that the Cas9-induced double-strand break is lethal to *Leptospira* spp. and, as an alternative, the catalytically inactive variant of the enzyme, dCas9, can be used to achieve gene silencing in both saprophytic and pathogenic species<sup>4, 5</sup>. By using the plasmid pMaOri.dCas9 as a backbone for sgRNA cassette ligation, specific and stable gene silencing can be obtained due to the expression of both dCas9 and sgRNA; dCas9-bound sgRNA will lead the protein to the desired target by Watson-Crick base pairing.

For complete gene silencing, the protospacer should be designed based on the template strand of the desired gene so that base pairing of the sgRNA occurs with the coding strand. Based on an average C+G content of 35% in *Leptospira* spp., the PAM 5'-NGG-3' will occur at least 3 times every 100 bp. Therefore, virtually any gene within the genome of *Leptospira* will contain at least one PAM. However, if the motif NGG is not found, the alternative NAG motif can be evaluated.

Previous gene silencing techniques, such as zinc fingers and TALE (transcription activator-like effectors), relied on the construction of one different protein to each target, making these techniques laborious and costly<sup>38</sup>. In the case of CRISPRi, the variable component is the sgRNA, making it necessary to only change the 20 bp at the 5' end. Complete, stable, and targeted gene silencing has been observed not only in *Leptospira* spp.<sup>4,5</sup>, but also in other bacteria<sup>8,39-41</sup>.

The development of HAN media<sup>13</sup> favored the recovery of mutants by drastically reducing the incubation time for colony formation and allowing *Leptospira* to grow at 37 °C. However, during the conjugation step, its use is not recommended since *E. coli* can vigorously proliferate in this media and overcome the intended 1:1 proportion between donor and recipient cells. At this stage, EMJH plus DAP is the better choice, since *E. coli* replicate poorly in this media. It is worth mentioning that some laboratories make *in-house* supplemented EMJH, which can contain additional components that might also support the growth of *E. coli* cells.

The conjugation protocol presented here was optimized for *L. interrogans* serovar Copenhageni strain Fiocruz L1-130, and it was also proven to be effective in the transformation of a recently isolated pathogenic strain from soil samples<sup>5</sup>. Initial attempts with different serovars of *L. borgpetersenii* species indicate lower conjugation efficiencies with the described protocol. Thus, when working with different species/serovars of *Leptospira*, optimal conditions for conjugation should be determined empirically, considering donor:recipient cell proportions, initial cell densities, conjugation media and time (24 and 28h). It is reasonable to assume that different *Leptospira* species and serovars will behave differently with different conjugation protocols.

Even though saprophytic *Leptospira* colonies are relatively easy to visualize on plates, pathogenic colonies can be more difficult to observe. Normally, by using HAN media supplemented with 0.4% rabbit serum and spectinomycin, transconjugant colonies can be observed at day 10. In our experience, colonies initially present as a transparent halo at the media surface. In the video protocol, denser colonies, after 14 days of growth, are shown since the transparent ones were difficult to film. At this stage, rotating the plate to achieve different light incidence and shifting between white and dark backgrounds can help identify colonies.

For mutant validation, immunoblotting offers a straightforward approach; however, since antibodies are not always available against target proteins, alternative strategies to validate gene silencing can be pursued. Quantitative reverse-transcriptase PCR (qRT-PCR) using primers for the target gene and a constitutive control is effective to validate gene silencing since sgRNA-guided dCas9 is responsible for blockage of gene transcription. If the target gene

encodes a clearly defined protein band in protein gels, SDS-PAGE can demonstrate silencing, and as per the *lipL32* gene silencing<sup>5</sup>. If LPS biosynthesis genes are silenced, LPS staining can be employed; in the case of silencing genes encoding for enzymes with well-defined substrates, kinetic assays with chromogenic substrates are valid strategies;  $\beta$ -galactosidase silencing in *L. biflexa* was validated by the use of X-gal and ONPG (ortho-Nitrophenyl- $\beta$ -galactoside) substrates<sup>4</sup>.

After confirmation of gene silencing, experiments can be designed to further evaluate phenotype. Binding assays can be performed in the case of silencing bacterial adhesins; serum-challenge assays confirmed the role of LigA and LigB in serum survival displayed by pathogenic *Leptospira*<sup>5</sup>. Mutants can also be used to inoculate animals to assess attenuation of virulence; in this case, animals inoculated with the mutant should be compared to those infected with cells containing pMaOri.dCas9 only.

In conclusion, the current protocol describes the application of CRISPRi for gene silencing in pathogenic *Leptospira* species using HAN media to facilitate mutant recovery within 10 days. Gene silencing combined with functional genomic analysis will improve our understanding of pathogenic mechanisms of *Leptospira*, and ultimately leading to the development of better prophylactic strategies for disease control.

#### ACKNOWLEDGMENTS:

USDA is an equal opportunity provider and employer. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information, and does not imply recommendation or endorsement by the U.S. Department of Agriculture. The Brazilian agency FAPESP (grant 2014/50981-0) financially supported this work; LGVF is funded with a fellowship from FAPESP (2017/06731-8 and 2019/20302-8). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation. The authors also thank Hannah Hill and Alexander Grimes from the USDA Visual Services for filming and editing the video protocol.

#### DISCLOSURES:


The authors have nothing to disclose.


#### REFERENCES:

1. Bharti, A. R. et al., Leptospirosis: A zoonotic disease of global importance. *Lancet Infectious Disease*. **3** (12), 757-771 (2003).
2. Costa, F. et al. Global morbidity and mortality of Leptospirosis: A systematic review. *PLoS Neglected Tropical Disease*. **9** (9), e0003898 (2015).
3. Shapiro, R. S. et al. A CRISPR-Cas9-based gene drive platform for genetic interaction analysis in *Candida albicans*. *Nature Microbiology*. **3** (1), 73-82 (2018).
4. Fernandes, L. G. V. et al., Gene silencing based on RNA-guided catalytically inactive Cas9 (dCas9): a new tool for genetic engineering in *Leptospira*. *Science Reports*. **9** (1), 1839 (2019).
5. Fernandes, L. G. V., Hornsby, R. L., Nascimento, A. L. T. O., Nally, J. E., Genetic manipulation of pathogenic *Leptospira*: CRISPR interference (CRISPRi)-mediated gene silencing and rapid mutant recovery at 37 °C. *Science Reports*. **11** (1), 1768 (2021).


- 468 6. Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive  
469 bacterial immunity. *Science*. **337** (6096), 816-821 (2012).
- 470 7. Qi, L. S. et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific  
471 control of gene expression. *Cell*. **152** (5), 1173-1183 (2013).
- 472 8. Choudhary, E., Thakur, P., Pareek, M., Agarwal, N., Gene silencing by CRISPR  
473 interference in mycobacteria. *Nature Communication*. **6**, 6267 (2015).
- 474 9. Zhukova, A. et al., Genome-wide transcriptional start site mapping and sRNA  
475 identification in the pathogen. *Frontiers in Cell and Infectious Microbiology*. **7**, 10 (2017).
- 476 10. Demarre, G. et al. A new family of mobilizable suicide plasmids based on broad host  
477 range R388 plasmid (IncW) and RP4 plasmid (IncPalpha) conjugative machineries, and their  
478 cognate *Escherichia coli* host strains. *Research in Microbiology*. **156** (2), 245-255 (2005).
- 479 11. Pappas, C. J., Benaroudj, N., Picardeau, M. A replicative plasmid vector allows efficient  
480 complementation of pathogenic *Leptospira* strains. *Applied Environmental Microbiology*. **81**  
481 (9), 3176-3181 (2015).
- 482 12. Fernandes, L. G. V., Nascimento, A. L. T. O. Specific gene silencing in *Leptospira biflexa*  
483 by RNA-guided catalytically inactive Cas9 (dCas9). *Methods in Molecular Biology*. **2134**, 109-  
484 122 (2020).
- 485 13. Hornsby, R. L., Alt, D. P., Nally, J. E. Isolation and propagation of leptospires at 37 °C  
486 directly from the mammalian host. *Science Reports*. **10** (1), 9620 (2020).
- 487 14. Haake, D. A., Hamster model of leptospirosis. *Current Protocols in Microbiology*.  
488 Chapter 12, Unit 12E.12 (2006).
- 489 15. Nascimento, A. L. et al. Comparative genomics of two *Leptospira interrogans* serovars  
490 reveals novel insights into physiology and pathogenesis. *Journal of Bacteriology*. **186** (7),  
491 2164-2172 (2004).
- 492 16. Nascimento, A. L. et al., Genome features of *Leptospira interrogans* serovar  
493 Copenhageni. *Brazilian Journal of Medical Biology Research*. **37** (4), 459-477 (2004).
- 494 17. Ren, S. X. et al. Unique physiological and pathogenic features of *Leptospira interrogans*  
495 revealed by whole-genome sequencing. *Nature*. **422** (6934), 888-893 (2003).
- 496 18. Bulach, D. M. et al. Genome reduction in *Leptospira borgpetersenii* reflects limited  
497 transmission potential. *Proceedings of the National Academy of Science U. S. A.* **103** (39),  
498 14560-14565 (2006).
- 499 19. Picardeau, M. et al. Genome sequence of the saprophyte *Leptospira biflexa* provides  
500 insights into the evolution of *Leptospira* and the pathogenesis of leptospirosis. *PLoS One*. **3**  
501 (2), e1607 (2008).
- 502 20. Fernandes, L. G. et al. OmpL1 is an extracellular matrix- and plasminogen-interacting  
503 protein of *Leptospira* spp. *Infections and Immunity*. **80** (10), 3679-3692 (2012).
- 504 21. Fernandes, L. G. et al. *Leptospira* spp.: Novel insights into host-pathogen interactions.  
505 *Veterinary Immunology and Immunopathology*. **176**, 50-57 (2016).
- 506 22. Castiblanco-Valencia, M. M. et al., Leptospiral immunoglobulin-like proteins interact  
507 with human complement regulators factor H, FHL-1, FHR-1, and C4BP. *Journal of Infectious*  
508 *Diseases*. **205** (6), 995-1004 (2012).
- 509 23. Choy, H. A. et al. The multifunctional LigB adhesin binds homeostatic proteins with  
510 potential roles in cutaneous infection by pathogenic *Leptospira interrogans*. *PLoS One*. **6** (2),  
511 e16879 (2011).
- 512 24. Siqueira, G. H. et al. The recombinant LIC10508 is a plasma fibronectin, plasminogen,  
513 fibrinogen and C4BP-binding protein of *Leptospira interrogans*. *Pathogen and Diseases*. **74**  
514 (2), (2016).

25. Teixeira, A. F. et al. Features of two new proteins with OmpA-like domains identified in the genome sequences of *Leptospira interrogans*. *PLoS One*. **10** (4), e0122762 (2015).
26. Kochi, L. T. et al. The interaction of two novel putative proteins of *Leptospira interrogans* with E-cadherin, plasminogen and complement components with potential role in bacterial infection. *Virulence*. **10** (1), 734-753 (2019).
27. Murray, G. L. et al. Genome-wide transposon mutagenesis in pathogenic *Leptospira* species. *Infections and Immunity*. **77** (2), 810-816 (2009).
28. Bourhy, P., Louvel, H., Saint Girons, I., Picardeau, M., Random insertional mutagenesis of *Leptospira interrogans*, the agent of leptospirosis, using a mariner transposon. *Journal of Bacteriology*. **187** (9), 3255-3258 (2005).
29. Pětrošová, H., Picardeau, M. Screening of a *Leptospira biflexa* mutant library to identify genes involved in ethidium bromide tolerance. *Applied Environmental Microbiology*. **80** (19), 6091-6103 (2014).
30. Slamti, L., Picardeau, M. Construction of a library of random mutants in the spirochete *Leptospira biflexa* using a mariner transposon. *Methods in Molecular Biology*. **859**, 169-176 (2012).
31. Croda, J. et al. Targeted mutagenesis in pathogenic *Leptospira* species: Disruption of the LigB gene does not affect virulence in animal models of leptospirosis. *Infections and Immunity*. **76** (12), 5826-5833 (2008).
32. Picardeau, M., Brenot, A., Saint Girons, I. First evidence for gene replacement in *Leptospira* spp. Inactivation of *L. biflexa* flaB results in non-motile mutants deficient in endoflagella. *Molecular Microbiology*. **40** (1), 189-199 (2001).
33. King, A. M. et al. High-temperature protein G is an essential virulence factor of *Leptospira interrogans*. *Infections and Immunity*. **82** (3), 1123-1131 (2014).
34. Lambert, A. et al. FlaA proteins in *Leptospira interrogans* are essential for motility and virulence but are not required for formation of the flagellum sheath. *Infections and Immunity*. **80** (6), 2019-2025 (2012).
35. Murray, G. L. et al. *Leptospira interrogans* requires heme oxygenase for disease pathogenesis. *Microbes and Infections*. **11** (2), 311-314 (2009).
36. Ristow, P. et al., The OmpA-like protein Loa22 is essential for leptospiral virulence. *PLoS Pathogens*. **3** (7), e97 (2007).
37. Sasaki, Y., et al., Leptospiral flagellar sheath protein FcpA interacts with FlaA2 and FlaB1 in *Leptospira biflexa*. *PLoS One*. **13** (4), e0194923 (2018).
38. Gaj, T., Gersbach, C. A., Barbas, C. F., ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. *Trends in Biotechnology*. **31** (7), 397-405 (2013).
39. Cress, B. F. et al. Rapid generation of CRISPR/dCas9-regulated, orthogonally repressible hybrid T7-lac promoters for modular, tuneable control of metabolic pathway fluxes in *Escherichia coli*. *Nucleic Acids Research*. **44** (9), 4472-4485 (2016).
40. Zhao, C., Shu, X., Sun, B. Construction of a gene knockdown system based on catalytically inactive ("dead") Cas9 (dCas9) in *Staphylococcus aureus*. *Applied Environmental Microbiology*. **83** (12), (2017).
41. Zhao, Y. et al. CRISPR/dCas9-mediated multiplex gene repression in *Streptomyces*. *Biotechnology Journal*. e1800121 (2018).



**Figure 2**



**Figure 3**





Click here to access/download  
**Table of Materials**  
**JoVE\_Materials.xls**



United States Department of Agriculture

---

Research, Education, and Economics  
Agricultural Research Service

March 2<sup>nd</sup>, 2021

Submission: JoVE62631

Dear Dr. Nguyen,

Thank you for your prompt review of our submission to JoVE entitled “Application of CRISPR interference (CRISPRi) for gene silencing in pathogenic species of *Leptospira*”. As requested, Figure 3 has been updated to show actual data generated from using the protocol rather than just an illustrated figure. The associated legend for figure 3 has also been updated.

If there is anything else we need to address, please let us know. Our video is also complete and is available for your review once a link to share it is provided.

Sincerely,

Luis Fernandes

Cc Jarlath Nally

## Supplementary File

The sgRNA cassette should be:

**cccgggGAACAAGAAAGAGTCAGAGAATTATTGAAGAGATACTCTTATACTACCGTCTTTGGAAGAATT  
TTCGCATGGATTTTAGATTTGCTGGACTGGTTGAAGCGATTTTTTCAAAAAAATAATCAATTTGTGTC  
TGAGATTTGAAAACGCTTGTTTGATAGTTTTTAAAGAATTTCTGATGTTCAATCGTATAGAAATTCTA  
AATTTAGAAATCATCCTTTACTTTTCTCTAAGACTTATATAACAATCGCTTTAAACTCAAATTATAATCTT  
TCAGATAAAAAATTATTCAATATTGATTTACAAAAAATTCCTAAGTTCATACCGTGATTTTCNNNNNN  
NNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAGTTAAATAAGGCTAGTCCGTTATCAACTTG  
AAAAAGTGGCACCGAGTCGGTGCTTTTTTcccggg**

Bold nucleotides refer to the *lipL32* promoter and underlined nucleotides refer to the dCas9 scaffold. XmaI restriction sites (cccggg) are included at both ends, for ligation at pMaOri.dCas9 plasmid.